Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 34,35€ (+69,38%). La mediana è 34,35€ (+69,38%).
| Acquista |
8 |
| Mantieni |
1 |
| Vendi |
2 |
Notizie Vai al feed delle notizie
Tactile Systems Technology reports 12% revenue growth to $329.5M for 2025
Tactile Systems Technology posted 2025 revenue of $329.5 million, up 12%, and ended the year with $83.4 million in cash. The company acquired Lymphotec and plans to integrate its fluid-monitoring technology to enhance patient surveillance and commercial workflows. Investments in a new CRM and expanded sales headcount are driving productivity gains, while updated Medicare coverage criteria have improved access to the FlexiTouch system. For 2026 the company issued guidance of 8%–11% revenue growth but warned a new Medicare prior authorization requirement for pneumatic compression devices could create a short-term headwind. » Altro su finance.yahoo.com
Tactile Systems misses EPS forecast in Q2 2025 but beats revenue expectations
Tactile Systems Technology missed earnings expectations in the second quarter of 2025, reporting EPS of $0.14, while revenue came in above forecasts at $78.9 million. The respiratory product segment saw particularly strong growth, but the missed EPS and a decline in adjusted EBITDA led to a slight drop in the share price. The company remains optimistic for the full year and expects revenue growth of 6-8%. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 75,09M | 12,17% |
| Utile lordo | 51,57M | 3,39% |
| Utile netto | 6,82M | 149,92% |
| EBITDA | 8,06M | 44,08% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 452,45M€ |
Numero di azioni | 22,56M |
Massimo/minimo a 52 settimane | 32,43€ - 11,00€ |
| Dividendi | No |
Beta | 0,82 |
Rapporto P/E | 21,43 |
Rapporto PEG | 0,28 |
Rapporto P/B | 2,37 |
Rapporto P/S | 1,50 |
Profilo aziendale
Tactile Systems Technology, Inc. ist ein Medizintechnikunternehmen, das sich mit der Entwicklung und Bereitstellung von medizinischen Geräten für chronische Krankheiten in den Vereinigten Staaten beschäftigt. Das Unternehmen bietet das Flexitouch Plus System an, ein pneumatisches Kompressionsgerät für die Behandlung von Lymphödemen; das Entre System, ein tragbares pneumatisches Kompressionsgerät, das für die Behandlung von Venenerkrankungen wie Lymphödemen und chronischer Veneninsuffizienz, einschließlich venöser Beingeschwüre, zu Hause verwendet wird; und AffloVest, einen tragbaren Hochfrequenz-Brustwand-Oszillationstest für die Behandlung von zurückgehaltenen Lungensekreten wie Bronchiektasien, zystischer Fibrose und verschiedenen neuromuskulären Erkrankungen. Das Unternehmen wurde 1995 gegründet und hat seinen Hauptsitz in Minneapolis, Minnesota.
| Nome | Tactile Systems Technology Inc |
| CEO | Sheri Louise Dodd |
| Sede centrale | Minneapolis,
mn Stati Uniti |
| Sito web | |
| Settore | Beni voluttuari |
| Industria | Beni durevoli per la casa |
| Quotazione in borsa | 28/07/2016 |
| Dipendenti | 1.086 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | TCMD |
Frankfurt | 3L3.F |
Düsseldorf | 3L3.DU |
München | 3L3.MU |
Scopri gli asset
Gli azionisti di Tactile Systems Technology Inc investono anche nei seguenti asset
